IGF1 and Alzheimer disease: For instance, in the Framingham cohort (n = 3,582; aged 65 ± 11 years), participants with IGF-1 in the lowest quartile had a 51% greater risk of developing AD and higher IGF-1 concentrations were associated with greater brain volumes in those without dementia [14].